Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (53)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pirker, R.
Right arrow Articles by Huber, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirker, R.
Right arrow Articles by Huber, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:833-835, 1995
© 1995 European Society for Medical Oncology

research-article

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

R. Pirker1,, G. Krajnik1, S. Zöchbauer1, R. Malayeri1, M. Kneussl2 and H. Huber1

1Department of Oncology, Clinic for Internal Medicine I
2Department of Pulmology, Clinic for Internal Medicine IV; University of Vienna Medical School Vienna, Austria

Correspondence to: R. Pirker, MX). Department of Oncology Clinic for Internal Medicine I University of Vienna Medical School Wahringer Gurtel 18–20 A-1090 Vienna, Austria

Background: Paclitaxel (Taxol®) as single agent has shown promising activity in advanced non-small-cell lung cancer (NSCLC). Because paclitaxel lends itself to combination with other anticancer drugs, we have determined the efficacy of paclitaxel combined with cisplatin in patients with advanced NSCLC in a phase II trial

Patients and methods: Twenty patients with NSCLC stage IIIB or IV were treated with paclitaxel (175 mg/m2) as a 3-hour infusion after standard premedication on day 1 and cisplatin (50 mg/m2 daily) on days 1 and 2. Treatment was repeated every 3 weeks

Results: All 20 patients were evaluable for response and toxic effects. Partial responses were seen in 7 (35%) patients and no change in 9 (45%) patients. Major side effects included leukopenia, anemia, alopecia and dose-limiting neurotoxicity

chemotherapy, cisplatin, neurotoxicity, non-small-cell lung cancer, paclitaxel, phase II trial, Taxol®


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
U. Gatzemeier, J. von Pawel, M. Gottfried, G. P. M. t. Velde, K. Mattson, F. DeMarinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, et al.
Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 19, 2000; 18(19): 3390 - 3399.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. P. Belani
Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer
Chest, April 1, 2000; 117 (2009): 144S - 151S.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J. Langer and D. S. Ettinger
The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy
Oncologist, April 1, 1998; 3(2): 67 - 85.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.